Edition:
United Kingdom

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.80USD
18 May 2018
Change (% chg)

$-0.16 (-16.67%)
Prev Close
$0.96
Open
$0.88
Day's High
$0.90
Day's Low
$0.78
Volume
500,613
Avg. Vol
86,047
52-wk High
$4.59
52-wk Low
$0.51

Select another date:

Thu, May 10 2018

BRIEF-Fibrocell Reports Q1 Loss Per Share $0.11

* FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights

* FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018

* FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING Source text: (http://bit.ly/2EaJQ01) Further company coverage:

Select another date: